



**NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT  
FOURTH QUARTER OF 2016 (2016Q4)**

**Substance Abuse Epidemiology Section  
Prescription Drug Overdose Prevention Program  
Injury and Behavioral Epidemiology Bureau  
Epidemiology and Response Division**

This report is produced quarterly to track indicators related to drug overdose prevention. The indicators reported here allow for the tracking of three key interventions for prescription drug overdose: improving prescribing of controlled substances, increasing the availability of treatment for opioid dependence, and the increasing availability of naloxone in the community.



This report is based on calendar quarters: Q1 is January-March of the calendar year. Data for this report was drawn from several sources:

1. The Prescription Monitoring Program (PMP) operated by the NM Board of Pharmacy, which collects data on every controlled substance prescription filled in New Mexico.
2. New Mexico Medicaid in the Human Services Department, for data on methadone treatment paid by Medicaid, and for data on claims paid for naloxone prescriptions at pharmacies.
3. The State Opioid Treatment Authority in the Human Services Department for data on methadone treatment programs operating in New Mexico.
4. The Syringe Services Program for data on naloxone distributed via syringe exchange sites




The PMP was migrated from one hardware/software system (platform) to another at the end of October 2016. The platform supports the collection and management of prescription data for the PMP. With the platform change, the process by which DOH receives and processed PMP data also changed. This may cause small differences in trends due to changes in the completeness of the data.

PMP usage data are not available for October 2016 at this time, so those data are not complete for Q4. Gray shading indicates parts of the tables with incomplete data.

## I. New Mexico Prescription Monitoring Program (PMP) Measures



## I. New Mexico Prescription Monitoring Program (PMP) Measures



## I. New Mexico Prescription Monitoring Program (PMP) Measures

### Totals

Year and Quarter	2015Q4	2016Q3	2016Q4	Quarterly % Change 2016Q3 vs 2016Q4	Quarterly % Change 2015Q4 vs 2016Q4
Total number of controlled substance patients	271,994	258,586	262,756	1.6%	-3.4%
<b>Number of patients receiving opioids</b>	190,899	176,005	180,082	2.3%	-5.7%
Number of opioid prescriptions filled (excluding buprenorphine/naloxone)	411,222	377,381	382,878	1.5%	-6.9%
Number of buprenorphine/naloxone prescriptions filled	15,193	16,530	18,043	9.2%	18.8%
Number of high dose (>=90 MME/day) opioid prescriptions excluding buprenorphine/naloxone	56,179	50,117	48,986	-2.3%	-12.8%
Total MME of opioids filled - excluding buprenorphine/naloxone	390,836,820	359,940,811	354,065,444	-1.6%	-9.4%
Total MME/prescription-day	65	63	62	-2.2%	-4.8%
Number of patients receiveing benzodiazepines	100,756	97,393	97,711	0.3%	-3.0%
Number of benzodiazepine prescriptions filled	224,973	214,126	215,252	0.5%	-4.3%
Number of high-dose(>=30 DME/day) benzodiazepine prescriptions filled	41,096	39,802	39,674	-0.3%	-3.5%
Total DME of benzodiazepines filled	127,774,291	122,434,678	121,705,077	-0.6%	-4.7%
Total DME/patient	1,268	1,257	1,246	-0.9%	-1.8%

\* The PMP platform changed in Q4 2016, which may impact comparabilty of data

\*\* PMP usage data are not available for October 2016

**SOURCE OF DATA:** NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients

MME = Morphine Milligram Equivalent; reference at [http://www.cdc.gov/drugoverdose/pdf/calculating\\_total\\_daily\\_dose-a.pdf](http://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf)

DME = Diazepam Milligram Equivalent; reference at <http://archinte.jamanetwork.com/article.aspx?articleid=217249>, 2004

Categories in **bold** were voted on as being of great interest by Members of the Prescription Drug Misuse and Overdose Prevention and Pain Management Advisory Council.

## I. New Mexico Prescription Monitoring Program (PMP) Measures

### Number of Patients with:

Year and Quarter	2015Q4	2016Q3	2016Q4	Quarterly % Change 2016Q3 vs 2016Q4	Quarterly % Change 2015Q4 vs 2016Q4
High dose opioids (>=90 MME/day)	19,872	17,904	17,997	0.5%	-9.4%
High dose benzodiazepines (>=30 DME/day)	18,118	17,592	17,531	-0.3%	-3.2%
Opioids >=90 days and <90% of days in past 6 months	27,361	26,096	25,888	-0.8%	-5.4%
Opioids >=90% of days in past 6 months	28,693	28,645	26,826	-6.4%	-6.5%
Benzodiazepines >=90 days and <90% of days in past 6 months	28,968	27,748	27,093	-2.4%	-6.5%
Benzodiazepines >=90% of days in past 6 months	25,624	25,585	23,889	-6.6%	-6.8%
<b>Overlapping prescriptions of opioids from different prescribers (&gt;=10 days total overlap)</b>	5,647	4,836	4,868	0.7%	-13.8%
<b>Overlapping prescriptions of benzodiazepines from different prescribers (&gt;=10 days total overlap)</b>	3,680	3,121	3,143	0.7%	-14.6%
<b>Concurrent opioid and benzodiazepines (&gt;=10 days overlap)</b>	28,628	25,828	26,066	0.9%	-8.9%
<b>High dose opioids (&gt;=90 MME/day) plus benzodiazepines</b>	6,395	5,514	5,389	-2.3%	-15.7%
<b>Multiple prescribers and pharmacies: 4 or more prescribers or 4 or more pharmacies in 3 months</b>	4,761	4,024	3,759	-6.6%	-21.0%
With PMP reports requested by practitioners**	57,993	69,814			
% of Chronic opioid users (>=90 days in the past 6 months) with a PMP request in the past 3 months**	40.6%	47.6%			

\* The PMP platform changed in Q4 2016, which may impact comparability of data

\*\* PMP usage data are not available for October 2016

**SOURCE OF DATA:** NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance

Categories in **bold** were voted-on as being of great interest by Members of the Prescription Drug Misuse and Overdose Prevention and Pain Management Advisory Council.

## I. New Mexico Prescription Monitoring Program (PMP) Measures


### New Mexico Prescribers with at least 20 controlled substance patients:

Year and Quarter	2015Q4	2016Q3	2016Q4	Quarterly % Change 2016Q3 vs 2016Q4	Quarterly % Change 2015Q4 vs 2016Q4
Total active controlled substance prescribers	3,295	3,262	3,244	-0.6%	-1.5%
Treatment (buprenorphine/naloxone) prescribers with at least 10 treatment patients	93	108	103	-4.6%	10.8%
Prescribers with at least 50% high dose of opioid prescriptions, excluding treatment prescribers	59	62	58	-6.5%	-1.7%
Prescribers with at least 50% high dose of benzodiazepine prescriptions	159	150	148	-1.3%	-6.9%
Prescribers with at least 25% of patients having concurrent opioids and benzodiazepines	30	32	25	-21.9%	-16.7%
High Volume - 10 or more controlled substance prescriptions per prescribing day	94	80	72	-10.0%	-23.4%
Some PMP Use: Requested reports on at least 25% of patients estimated to require them**	475	590			
Zero PMP Use: Requested no PMP reports on patients filling Controlled Substances**	904	722			

\* The PMP platform changed in Q4 2016, which may impact comparability of data

\*\* PMP usage data are not available for October and November 2016

**SOURCE OF DATA:** NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance



## II. Medication Assisted Treatment (Buprenorphine/naloxone and methadone)

### Measures

Year and Quarter	2015Q4	2016Q3	2016Q4	Quarterly % Change 2016Q3 vs 2016Q4	Quarterly % Change 2015Q4 vs 2016Q4
Treatment (buprenorphine/naloxone) prescribers with at least 10 treatment patients	93	108	103	-4.6%	10.8%
Number buprenorphine/naloxone patients (>=10 days)	4006	4282	4668	9.0%	16.5%
Number buprenorphine/naloxone prescriptions filled	15193	16530	18043	9.2%	18.8%
<b>Medicaid Methadone Treatment</b>					
Number of distinct individuals with methadone claims paid by NM Medicaid	3470	3916	4126	5.4%	18.9%
Number of distinct NM Medicaid providers of methadone	14	9	10	11.1%	-28.6%


Methadone Treatment Programs by Survey Date	9/2015	3/2017
Number of Methadone Treatment Programs	14	15
Number of Methadone Treatment Patients in those Programs	4,425	5,531

\* The PMP platform changed in Q4 2016, which may impact comparability of buprenorphine/naloxone data; methadone data are not affected by the PMP change.

#### Sources:

Buprenorphine/naloxone data: NM Prescription Monitoring Program

Methadone data: NM Human Services Department, State Opioid Treatment Authority; NM Medicaid



### III. Naloxone Distribution and Usage Measures

Year and Quarter	2015Q4	2016Q3	2016Q4	Quarterly % Change 2016Q3 vs 2016Q4	Quarterly % Change 2015Q4 vs 2016Q4
Total number of NM Government Program Naloxone Enrollments	575	465	265	-43.0%	-53.9%
Total Number of NM Naloxone Doses distributed	1587	1409	732	-48.0%	-53.9%
Total Number of NM Reported Reversals	166	161	93	-42.2%	-44.0%
Pharmacies Presenting Medicaid Naloxone Claims	32	81	72	-11.1%	125.0%
Number of Medicaid Claims Processed	68	394	271	-31.2%	298.5%

Reported Reversals are not necessarily individual level data, as one person could have overdosed and been reversed more than once

An outpatient pharmacy could present claims in more than one quarter. The total number has been obtained by only counting each pharmacy once (140 individual outpatient pharmacies have presented claims, including 2 outside NM). 361 Pharmacies had a NM address, according to the Board of Pharmacy

Data last updated March 6th, 2017. Harm Reduction Services data through 30 December, 2016

